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Summary
Objectives: To determine the occurrence of extended-spectrum beta-lactamase
(ESBL)-producing Enterobacteriaceae in Bahrain.
Methods: Retrospective analysis of records (January 2005—December 2006) at the
Microbiology Laboratory of the Salmaniya Medical Complex, Bahrain which is the
major national diagnostic laboratory.
Results: Out of a total of 11,886 member of family of Enterobacteriaceae isolated,
2695 (22.6%) were ESBL producers. Majority of ESBL isolates were from inpatients
(n = 2363; 87.7%). Escherichia coli (52.2%) and Klebsiella pneumoniae (24.3%) were
predominant and distributed comparatively in the hospital wards while Proteus spp.
(17.6%) was predominant in medical wards. Urine was the major source (52.2%) with
low occurrence in blood cultures. No carbapenem resistant isolates was identiﬁed
but resistance to three classes of antibiotics was exhibited by >25% of the isolated
ESBL strains. Nitrofurantoin resistance was identiﬁed in 38.2% of urinary isolates.
Conclusion: This is the ﬁrst report from Bahrain and it indicates that the prevalence
of ESBL-producing isolates is high. Carbapenems were the most active drug against
the ESBL-producing isolates. We recommend strict infection control to prevent traf-
ﬁcking into the community.
© 2009 Published by Elsevier Limited on behalf of King Saud Bin Abdulaziz University
for Health Sciences. All rights reserved.
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Introduction
Globally there is a continuing upward trend in
the prevalence of pathogens producing extended-
spectrum beta-lactamases (ESBLs). As infections
caused by these ESBL-producing organisms are asso-
ciated with higher rates of mortality, morbidity as
well as health care costs. This upward trend is
of concern to health care providers. ESBL arises
as a result of mutations in the TEM-1, TEM-2 or
SHV-1 genes which are commonly found in the
Enterobacteriaceae family [1]. Others enzymes,
notably members of the cefotaxime resistance
family (CTX-M), represent plasmid acquisition of
broad-spectrum beta-lactamases originally deter-
mined by chromosomal genes. These mutations
result in alterations in the amino acid conﬁg-
uration thus conferring on these enzymes the
ability to hydrolyze a broader spectrum of beta-
lactam antibiotics including penicillins, oxyimino-
cephalosporins and monobactams. However these
plasmid-mediated enzymes have no detectable
activity against cephamycins or the carbapenems
(imipenem and meropenem). They are also gen-
erally susceptible to beta-lactamase inhibitors,
such as clavulanate, sulbactam, and tazobactam
These ESBLs are most commonly identiﬁed in
Gram-negative organisms, primarily in Klebsiella
pneumoniae, Klebsiella oxytoca, and Escherichia
coli but they have also been described in Acineto-
bacter, Burkholderia, Citrobacter, Enterobacter,
Morganella, Proteus, Pseudomonas, Salmonella,
Serratia, and Shigella spp. [2].
Since the 1983 report of the ﬁrst outbreak involv-
ing ESBL-producing organisms in Germany, other
reports from Europe, the USA and the Far East
have conﬁrmed the role of ESBL-producing organ-
isms as important agents in nosocomial infections
[1,3]. In recent years, variants of the original
ESBL enzymes such as CTX-M beta-lactamases
have become widespread with an endemic situ-
ation now prevailing in Asia, South America and
parts of Europe [4—6]. As evidence indicates
regional/national diversity in the prevalence of
ESBL isolates there is a need for continued surveil-
lance. Up to date, there have been no reports
documenting the prevalence of ESBL isolates in
the Kingdom of Bahrain. However data from other
countries within the Arabian Gulf region suggest
ESBL isolates constitute a major problem in nosoco-
mial and community acquired infections with rates
ranging from 7.5% to 31.7% reported in Kuwait to
the highest of 41% which we have recently shown
in data from United Arab Emirates [7—9]. In this
report, we present the ﬁrst data on ESBL-producing
isolates identiﬁed in the Kingdom of Bahrain.
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aterials and methods
etting
he Kingdom of Bahrain is a group of small islands
ocated in the Arabian Gulf region with a population
f approximately 650,000. The Salmaniya Medical
omplex (SMC) is a 1000-bed hospital that serves
s a secondary and tertiary referral center for spe-
ialist care, laboratory diagnosis and admissions.
he microbiology laboratory processes specimens
or inpatients as well as outpatients seen at SMC
linics and primary health care facilities.
ata collection
etrospective analysis of laboratory records at SMC
ver a 2-year period from January 2005 to Decem-
er 2006 was carried out to identify ESBL-producing
solates detected during the study period. Only one
ositive culture per patient was included hence
epeated positive cultures from the same patient
ere excluded from the analysis. Data on patient
emographics, specimen source (inpatient or out-
atient), specimen type as well as the antibiotic
usceptibility proﬁle of the isolates were recorded.
etection of ESBL isolates
uring the study period, bacterial identiﬁcation,
creening for ESBL and antimicrobial susceptibil-
ty testing were performed with the BD PhoenixTM
Becton Dickinson Diagnostic Systems, MD, USA)
utomated Microbiology system which incorporates
he BDXpert system. Speciﬁcally for ESBL detection,
he PhoenixTM ESBL test used ﬁxed concentrations
f the following drugs or drug combinations: cefpo-
oxime, ceftazidime, ceftazidime plus clavulanic
cid (CA), cefotaxime plus CA, and ceftriaxone
lus CA. The isolates were subcultured on Mac-
onkey agar to obtain a pure culture from which a
.5 McFarland suspension was obtained and tested
ccording to the manufacturer provided protocol.
onﬁrmation of the ESBL phenotype was carried
ut using the double disc diffusion method. This
as carried out using antibiotic discs containing a
ombination of cephalosporin plus clavulanic acid
n conjunction with a corresponding cephalosporin
isc alone and interpreted according to CLSI guide-
ines [10]. The following antibiotic discs were used:
eftazidime (CAZ 30g), ceftazidime plus clavu-
anic acid (CAZ/CA 30/10g), cefotaxime (CTX
0g) and cefotaxime plus clavulanic acid (CTX/CA
0/10g) and were all obtained from Becton Dick-
nson, USA. Brieﬂy, isolates were subcultured on
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Table 1 ESBL-producing isolates identiﬁed
2005—2006 at SMC Bahrain.
ESBL isolate Number of isolates %
Escherichia coli 1414 52.5
Klebsiella pneumoniaea 654 24.3
Proteus spp.b 473 17.6
Citrobacter spp. 64 2.4
Enterobacter spp. 62 2.3
Providencia spp. 25 0.9
Morganella morganii 3 0.1
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acConkey agar and 0.5 McFarland standard pre-
ared from the pure colonies. These were then
noculated on Mueller Hinton agar plates, antibi-
tic discs were applied the plates were incubated
n ambient air at 35 ◦C for 16—18 h. The diameter of
he zones of inhibition were measured and ≥5mm
ncrease in the zone of inhibition for the CAZ/CLA
nd CTX/CLA containing disc vs. the corresponding
AZ or CTX disc was considered positive for ESBL.
Using the BD PhoenixTM system, we assessed
he susceptibility patterns of the ESBL-
roducing isolates to a panel of antibiotics
ncluding amoxicillin/clavulanate, trimethoprim-
ulfamethoxazole, ciproﬂoxacin, gentamicin,
mipenem, meropenem and piperacillin/
azobactam, according to manufacturer rec-
mmended protocol. ESBL K. pneumoniae ATCC
00603, E. coli ATCC 25922 were used as a positive
ontrol and negative control, respectively. In
ddition, antibiotic sensitivity to imipenem and
eropenem using the disc diffusion susceptibility
esting method was also carried out. The antibiotic
iscs used were imipenem 10g and meropenem
0g and results were interpreted according to
anufacturer provided guidelines. All urinary
solates were tested for susceptibility to nitrofu-
antoin. Data analysis (chi-squared test) was done
sing Sigma Stat ver 3.5 (Systat Software Inc., San
ose, California, USA) and p < 0.05 was considered
tatistically signiﬁcant.
esults
ut of a total of 11,886 member of family of
nterobacteriaceae isolated, 2695 (22.6%) were
SBL producers. The mean age of the patients
as 52.6± 24.8 years with a female preponderance
55.7% vs. 44.3% males). Majority of isolates (2363;
t
b
n
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Figure 1 Distribution of ESBL producers aTotal 2695 100
a No Klebsiella oxytoca identiﬁed.
b Proteus mirabilis and Proteus vulgaris.
7.7%) were obtained from inpatients at SMC. E.
oli (1414) and K. pneumoniae (654) were the
redominant Enterobacteriaceae. Table 1 shows
he distribution of the different bacterial isolates.
rine was the major source of ESBL isolates (1406;
2.2%) and 26.9% (725) were from wound swabs/pus
hile 13.2% (357) were identiﬁed in respiratory
pecimens including sputum, deep tracheal aspi-
ate and bronchioalveolar lavage. The occurrence
f ESBL producers in bacteriaemia was low as
nly 7.7% (207) were from blood cultures. Provi-
entia spp. were isolated mainly from respiratory
pecimens (21/25) while Morganella morganii was
solated from wound (n = 2) and urine (n = 1). The
istribution of the remaining isolates according to
pecimen type showed that a signiﬁcantly higher
roportion of urinary isolates were E. coli (68.3%);
< 0.05 and for respiratory specimens both K. pneu-
oniae (40.2%) and Proteus spp. were predominant
37.5%) (Fig. 1). With the exception of Citrobac-
er and Enterobacter, the distribution of the other
acteria in wound/pus and blood specimens was
ot statistically signiﬁcant (Fig. 1). As E. coli, K.
neumoniae and Proteus spp. constitute 94.4% of
ccording to type of clinical specimen.
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TFigure 2 Distribution of ESBL-produ
our ESBL isolates, further analysis was carried out
only for these. The distribution of these isolates in
the hospital units showed that both E. coli and K.
pneumoniae were globally distributed being preva-
lent in comparable proportion in all the wards
(Fig. 2). However, while the highest number of E.
coli isolates were from the obstetric and gynae-
cology unit, K. pneumoniae was most prevalent in
the paediatric unit. In contrast, Proteus spp. was
mainly prevalent in the medical unit at a signiﬁ-
cantly higher number compared to the other units
in the hospital and it was notable that no Pro-
teus isolates were obtained from the paediatric unit
(Fig. 2).
Over 25% of E. coli, K. pneumoniae and
Proteus spp. isolates were resistant to the
different classes of antibiotics tested (beta-
lactams, quinolones and aminoglycosides) except
for piperacillin/tazobactam where only 12.6%
of Proteus spp. were resistant (Fig. 3). For
the beta-lactam/beta-lactamase inhibitor combi-
nations, there was a high degree of resistance
to amoxicillin/clavulanate (>70% of isolates).
However, compared to amoxicillin/clavulanate,
a
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Figure 3 Antibiotic susceptibility of ESBL producers isol
piperacillin/tazobactam; CIP: ciproﬂoxacin; GEN: gentamicinisolates in different wards in SMC.
he proportion of isolates showing resistance to
iperacillin/tazobactam was signiﬁcantly lower
p < 0.05) (Fig. 2); which was consistent with
ther studies [11]. The likely explanation for this
bservation is that the majority of our strains
ight be of CTX-M type which is better inhibited
y tazobactam than by clavulanate. The highest
egree of resistance to ciproﬂoxacin, gentamicin
nd trimethoprim-sulfamethoxazole was seen with
roteus spp. Susceptibility to nitrofurantoin was
arried out for 1547 urinary isolates of which 591
38.2%) showed resistance. All isolates were sus-
eptible to both imipenem and meropenem using
oth the BD automated system and disc diffusion
ethod.
iscussion
his is the ﬁrst report on the prevalence and
ntibiotic-susceptibility pattern of ESBL-producing
ram-negative bacteria isolated in Bahrain, giving
ﬁrst insight into the occurrence of these iso-
ates in the country. The ESBL detection rate of
ated at SMC. AUG: amoxicillin/clavulanic acid; TZP:
; SXT: trimethoprim-sulfamethoxazole.
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2.8% is reﬂective of national prevalence as SMC is
he major national tertiary hospital and the micro-
iology laboratory processes specimens obtained
rom inpatients at SMC, as well as outpatient clin-
cs and primary care facilities across the country.
eported national data show that, in Europe, the
revalence of ESBL ranges from a low of 3% in Swe-
en to as high as 34% in Portugal [12], 30—60%
n South America while in Asia surveys have indi-
ated ESBLs detection ranging from 5% to 8% in
solates from Korea, Japan Malaysia and Singapore
ith higher rates of up to 24% for other Asian coun-
ries [13—15]. Within the Arabian Gulf region, the
owest ESBL prevalence was described in a report
rom Kuwait (7.5%) [7]. However in another study a
igher percentage was reported (31.7%) [8]. In UAE
he prevalence of ESBL was shown to be 41% [9].
owever, in both cases the study population were
npatients only. ESBL detection among inpatients
nd outpatients in a maternity unit in the eastern
egion of Saudi Arabia was reported as 27.5% but
nly K. pneumoniae isolates were studied [16]. In
002, Babay [17] reported ESBL production in 36%
f Enterobacteriaceae from inpatients in a hospi-
al in Riyadh. More recently, 15.8% and 8.9% ESBL
revalence were reported in blood cultures and uri-
ary isolates, respectively [18,19]. Thus, compared
o regional and international data, the ESBL detec-
ion rate described here tends to be towards the
pper end of the spectrum and is therefore a cause
or concern.
While ESBL isolates remain important in noso-
omial infections, emerging data from parts of
urope, Asia and South America indicates that
ommunity acquired infections caused by ESBL-
roducing strains in particular those that harbour
he CTX-M gene is now endemic in many coun-
ries and this trend has been accompanied by the
ecognition of E. coli as the major source of ESBLs
n the community [20—22]. In contrast, major-
ty (∼88%) of ESBL producers in our setting were
solated from inpatients which indicates that infec-
ions associated with ESBL-producing pathogens in
ur population still remain largely nosocomial in
ature.
A predominance of either K. pneumoniae or E.
oli has often been reported among the ESBL iso-
ates identiﬁed in different geographical regions.
n Pakistan a prevalence of ESBL-producing K.
neumoniae vs. ESBL-producing E. coli (70% vs.
8.6%) has been reported [23] and in Italy a 2003
ationwide survey found that the most prevalent
SBL-positive species among hospitalized patients
as E. coli a switch from the predominance of K.
neumoniae in 1999 [24]. The predominant ESBL
roducer in our setting is E. coli accounting for
w
o
o
n
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ver half of the ESBL isolates identiﬁed. However,
here was no signiﬁcant difference in the distri-
ution of E. coli and K. pneumoniae ESBL isolates
n the wards within the hospital. Thus, given the
lobal distribution of these isolates, particularly E.
oli, unless strict infection control measures are
nforced, there is the high likelihood of trafﬁck-
ng of these ESBL producers from the hospital into
he community. This is particularly pertinent as the
ajority of ESBL isolates were from urine speci-
ens and the detection of EBSL producers in urine
as been described as an epidemiologic marker of
olonization and potential for trafﬁcking [25].
The antimicrobial susceptibility results show
hat both imipenem and meropenem remain the
ost effective class of drugs for ESBL isolates
oth showed full susceptibility with the two test-
ng methods we used. However, there remains a
eed for continued surveillance and judicious use of
hese antibiotics as a recent report from our region
as documented the occurrence of carbapenem
esistant E. coli isolate [9]. As new ﬁndings indicate
hat the spread of CTX-M type ESBLs, especially
n E. coli, may provide a favorable background for
election of carbapenem resistance [26] molecular
haracterization of the ESBL isolates in our set-
ing is needed. For the other classes of antibiotics
ested, >25% of the ESBL isolates showed resis-
ance to the classes of antibiotics tested. This level
f resistance perhaps represents the higher end
f the spectrum relative to other reported data
rom the Arabian Gulf Region. This is of concern
s clinically it indicates that there are limitations
n the antibiotic choices available for the treat-
ent of these infections. Studies have indicated
relationship between antibiotic usage and resis-
ance and we speculate that similar scenario may
e at play in our setting as recent reports have
hown that there is a high level of antibiotic pre-
cription and misuse occurring in Bahrain [27]. The
se of beta-lactam/beta-lactamase inhibitor com-
inations for the treatment of infections caused
y ESBL-producing organisms has been associ-
ted with treatment failures. The high level of
esistance to amoxicillin-clavulanate indicates it
imited use for treatment of ESBL infections in our
etting. However, relative to ciproﬂoxacin, gen-
amicin and trimethoprim-sulfamethoxazole, our
SBL isolates show higher levels of susceptibility to
iperacillin/tazobactam. The progressive increase
f infections caused by ESBL-producing bacteria
ith their attendant cross-resistance to antibiotics
f different classes has resulted in a re-evaluation
f the potential use of old antimicrobials such as
itrofurantoin. Our data presented herein repre-
ents the ﬁrst report on nitrofurantoin for urinary
[[
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[
[
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ESBL-producing isolates in our region. The ﬁnding
indicates that only about two-thirds of the isolates
are sensitive to nitrofurantoin. This is much lower
than other reports which have shown >88% suscep-
tibility in surveys in USA, 89% in India and 98% in
Hong Kong [28—30]. Although based on these data
from other countries, it has been suggested that
nitrofurantoin may be considered as an alterna-
tive therapeutic agent for urinary tract infections
caused by ESBL producers, our ﬁndings indicate that
responses may be less than satisfactory in our set-
ting in view of the degree of resistance present.
In conclusion, these ﬁndings indicate although
there is a high prevalence of ESBL-producing bac-
teria in our setting, it remains largely a nosocomial
infection. However, in view of the global distribu-
tion of these isolates in the hospital the potential
for trafﬁcking remains a high possibility. Further
work on themolecular characterization of ESBL pro-
ducers isolated in Bahrain and an urgent need for
control measures to reduce the spread of these
pathogens is recommended.
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